Upgrade to SI Premium - Free Trial

BioCryst Pharma (BCRX)

9.38 -0.13 (1.37%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

BioCryst to Report Second Quarter 2026 Financial Results on August 5 July 22, 2026 7:00 AM - Globe NewsWire BioCryst Pharma (BCRX) Reiterated at Market Outperform by Citizens on Orladeyo Potential July 17, 2026 5:10 AM - StreetInsider BioCryst names David Jenkins as chief scientific officer July 15, 2026 7:01 AM - StreetInsider BioCryst Appoints David W. Jenkins as Chief Scientific Officer July 15, 2026 7:00 AM - StreetInsider JPMorgan Resumes BioCryst Pharma (BCRX) at Neutral July 13, 2026 3:15 AM - StreetInsider BioCryst Pharma (BCRX) PT Raised to $14 at RBC Capital July 7, 2026 7:55 AM - StreetInsider BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 2, 2026 7:00 AM - Globe NewsWire BioCryst Pharma (BCRX) PT Raised to $17 at Jefferies June 30, 2026 4:42 AM - StreetInsider Form 8-K BIOCRYST PHARMACEUTICALS For: Jun 25 June 29, 2026 7:07 AM - SEC Filing BioCryst to close Birmingham lab and shift to external R&D model June 29, 2026 7:00 AM - StreetInsider BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility June 29, 2026 7:00 AM - StreetInsider Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: Milne Jill C. June 15, 2026 4:32 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: Galson Steven K June 15, 2026 4:31 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: LEVIN ALAN G June 15, 2026 4:29 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: Frank Steven June 15, 2026 4:16 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: SANDERS MACHELLE June 15, 2026 4:15 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: MILANO VINCENT June 15, 2026 4:12 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: Stonehouse Jon P June 15, 2026 4:10 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: McKee Amy E June 15, 2026 4:08 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: HEGGIE THERESA June 15, 2026 4:06 PM - SEC Filing Form 8-K BIOCRYST PHARMACEUTICALS For: Jun 11 June 12, 2026 4:11 PM - SEC Filing BioCryst presents HAE treatment data at European allergy meeting June 12, 2026 7:00 AM - StreetInsider BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting June 12, 2026 7:00 AM - Globe NewsWire BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 9, 2026 4:05 PM - Globe NewsWire Form 4 BIOCRYST PHARMACEUTICALS For: May 29 Filed by: Milne Jill C. June 2, 2026 4:16 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: May 29 Filed by: Stonehouse Jon P June 2, 2026 4:14 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: May 29 Filed by: McKee Amy E June 2, 2026 4:11 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: May 29 Filed by: MILANO VINCENT June 2, 2026 4:09 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: May 29 Filed by: Frank Steven June 2, 2026 4:07 PM - SEC Filing BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting May 27, 2026 7:00 AM - Globe NewsWire Form 4 BIOCRYST PHARMACEUTICALS For: May 18 Filed by: McKee Amy E May 19, 2026 4:08 PM - SEC Filing Form 144 BIOCRYST PHARMACEUTICALS Filed by: McKee Amy E May 18, 2026 4:48 PM - SEC Filing Form 4 BIOCRYST PHARMACEUTICALS For: May 13 Filed by: Barnes Alane P May 15, 2026 4:13 PM - SEC Filing Form 144 BIOCRYST PHARMACEUTICALS Filed by: Barnes Alane P May 13, 2026 1:06 PM - SEC Filing BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 May 13, 2026 7:00 AM - Globe NewsWire Form SCHEDULE 13G BIOCRYST PHARMACEUTICALS Filed by: STATE STREET CORP May 12, 2026 10:00 AM - SEC Filing BioCryst Pharma (BCRX) PT Raised to $28 at Citizens Amid Steady New Patient Starts May 7, 2026 5:02 AM - StreetInsider Form 10-Q BIOCRYST PHARMACEUTICALS For: Mar 31 May 6, 2026 4:08 PM - SEC Filing Form 8-K BIOCRYST PHARMACEUTICALS For: May 06 May 6, 2026 7:08 AM - SEC Filing BioCryst Pharma (BCRX) Misses Q1 EPS by 303c ; Offers Guidance May 6, 2026 7:05 AM - StreetInsider BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update May 6, 2026 7:00 AM - Globe NewsWire BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 5, 2026 7:01 AM - Globe NewsWire Form 8-K BIOCRYST PHARMACEUTICALS For: May 04 May 4, 2026 7:07 AM - SEC Filing BioCryst licenses navenibart to Neopharmed Gentili for European market May 4, 2026 7:01 AM - StreetInsider BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema May 4, 2026 7:00 AM - Globe NewsWire Form SCHEDULE 13G BIOCRYST PHARMACEUTICALS Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 29, 2026 5:03 PM - SEC Filing BioCryst to Present at Upcoming Investor Conferences April 28, 2026 7:00 AM - Globe NewsWire Full Article List